Poseida Therapeutics, Inc. PSTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 03/05/21 EST
8.63quote price arrow down-0.65 (-7.00%)
Volume
1,062,593
52 week range
7.63 - 17.62

...

Loading . . .

KEY STATS

  • Open9.35
  • Day High9.72
  • Day Low8.25
  • Prev Close9.28
  • 52 Week High17.62
  • 52 Week High Date07/17/20
  • 52 Week Low7.63
  • 52 Week Low Date08/24/20
  • Market Cap533.51M
  • Shares Out61.82M
  • 10 Day Average Volume0.51M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.93
  • P/E (TTM)-4.46
  • Fwd P/E (NTM)-2.96
  • EBITDA (MRQ)-100.074M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)9.82%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Poseida Therapeutics, Inc. News

There is no recent news for this security.

Latest PSTX News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac deoxyribonucleic acid (DNA) Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and adeno-associated virus (AAV)-based gene delivery technologies. The Company’s product candidate portfolio includes...
Eric Ostertag M.D. Ph.D.
Chief Executive Officer
Kerry Ingalls
Chief Operating Officer
Mark Gergen J.D.
Chief Financial Officer
Johanna Mylet CPA
Vice President - Finance
Address
9390 TOWNE CENTRE DRIVE, SUITE 200
San Diego, CA
92121
United States